New BRCA-targeting drug could treat advanced prostate cancer
Talazoparib delayed disease progression in Phase II trial
Read Moreby Lucy Parsons | Aug 23, 2021 | News | 0
Talazoparib delayed disease progression in Phase II trial
Read Moreby Lucy Parsons | Jun 18, 2021 | News | 0
POLQ inhibitors could be used to kill PARP inhibitor-resistant cancer cells
Read Moreby Selina McKee | Jun 4, 2021 | News | 0
Lynparza is the first medicine targeting BRCA mutations to show clinical benefit in adjuvant setting
Read Moreby Anna Smith | Aug 7, 2019 | News | 0
The treatment is the only PARP inhibitor with positive Phase III results in four different cancer types – ovarian, breast, pancreatic and prostate.
Read Moreby Anna Smith | Apr 5, 2019 | News | 0
The expansion will use BRACAnalysis CDx to identify germline BRCA mutations.
Read Moreby Anna Smith | Dec 20, 2018 | News | 0
Lynparza has been approved in the US for first-line maintenance therapy of BRCA-mutated advanced ovarian cancer.
Read Moreby Selina McKee | Nov 9, 2018 | News | 0
The National Institute for Health and Care Excellence has ruled against expanding use of AstraZeneca/MSD’s Lynparza to a wider patient population with ovarian cancer.
Read Moreby Selina McKee | Aug 14, 2018 | News | 0
The Scottish Medicines Consortium has approved funding for four newly licensed medicines, expanding NHS treatments options in Scotland for ovarian cancer, lung cancer, urea cycle disorders and acute hereditary angioedema.
Read Moreby Selina McKee | Jun 27, 2018 | News | 0
AstraZeneca and MSD have unveiled trial results showing that Lynparza significantly extended the time patients with ovarian cancer lived without their disease worsening in the first-line maintenance setting, which could significantly expand the drug’s reach.
Read Moreby Selina McKee | Jun 8, 2018 | News | 0
Regulators on both sides of the Atlantic have accepted for review Pfizer’s PARP inhibitor talazoparib as a treatment for women with a hereditary BRCA mutation.
Read Moreby Selina McKee | May 9, 2018 | News | 0
European regulators have approved a tablet formulation and new dosing regimen for AstraZeneca and MSD’s Lynparza to treat a wider range of patients with ovarian cancer.
Read Moreby Selina McKee | Jan 18, 2018 | News | 0
Research led by Queen Mary University of London has concluded that whole-population testing for mutations linked with a higher risk of breast and ovarian cancer is cost-effective.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
